Skip to content

Drug interactions

Bicalutamide + Sparsentan

Severity: Minor

Bicalutamide and Sparsentan: minor interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Sparsentan is a CYP3A4 substrate, and moderate inhibitors can raise its exposure. Bicalutamide is a weak inhibitor, so the effect is expected to be small.

What this interaction means in plain words

Bicalutamide and Sparsentan have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.

Bicalutamide belongs to Endocrine; Sparsentan belongs to Genitourinary.

Evidence level: Low

Why it happens

Weak CYP3A4 inhibition by bicalutamide may modestly raise sparsentan levels.

What to do

No dose change; monitor blood pressure, potassium, edema and liver and kidney function as routinely required for sparsentan.

What to ask your pharmacist

  • Is there anything I should notice while taking both?
  • Do I need to tell my doctor at the next visit?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Bicalutamide and Sparsentan, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Bicalutamide with Sparsentan?

MediHelp rates the interaction as minor. Bicalutamide and Sparsentan have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Sparsentan is a CYP3A4 substrate, and moderate inhibitors can raise its exposure. Bicalutamide is a weak inhibitor, so the effect is expected to be small.

How serious is the interaction between Bicalutamide and Sparsentan?

MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change; monitor blood pressure, potassium, edema and liver and kidney function as routinely required for sparsentan.

What other medicines interact with Bicalutamide?

MediHelp also lists interactions of Bicalutamide with, for example, Lomitapide, Aminolevulinic acid, Eliglustat. The full list is on the Bicalutamide page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in